The landscape of global oncology and medical diagnostics underwent a seismic shift this year as Abbott completed its $21 billion acquisition of Exact Sciences, a move that signals the healthcare giant’s aggressive entry into the rapidly evolving field of cancer screening. Finalized in March, the acquisition integrates one of the most successful diagnostic portfolios in recent history into Abbott’s established infrastructure, adding more than $3 billion in annual revenue to a diagnostics segment that now exceeds $12 billion in total sales. This strategic consolidation comes at a time when the medical community is pivoting toward "liquid biopsies" and blood-based screening tests, which promise earlier detection, more targeted interventions, and a personalized approach to the entire cancer care continuum.
The acquisition brings into the Abbott fold the flagship Cologuard stool test—the first non-invasive screening tool of its kind—and the Oncotype DX genomic tests, which have become the standard of care for informing treatment pathways in breast, colon, and prostate cancers. However, the deal is not merely about legacy products; it is a forward-looking investment in the next generation of diagnostic technology. In 2025, the division launched Oncodetect, a molecular residual disease (MRD) test designed to identify circulating tumor DNA (ctDNA) in the blood following treatment, and Cancerguard, a multi-cancer early detection (MCED) blood test. These innovations represent a transition from reactive diagnostics to a longitudinal model of patient management.
A Vision for the Cancer Care Continuum
At the heart of Abbott’s new strategy is the concept of a "cancer care continuum," a philosophy that views the disease not as a single event but as a lifelong journey requiring constant, data-driven oversight. Jorge Garces, Abbott’s divisional vice president of cancer diagnostics R&D and former chief science officer at Exact Sciences, emphasizes that the goal is to provide the right information at every critical juncture—from initial screening and diagnosis to therapeutic decision-making and post-treatment monitoring.
The personal impact of these technologies is often as profound as their clinical utility. Garces noted that his own family experienced the benefits of the portfolio when his wife was diagnosed with breast cancer. The use of Abbott’s Riskguard testing allowed for a more informed decision regarding the aggressiveness of her surgery, while the Oncotype DX test provided a low recurrence score, ultimately sparing her from unnecessary chemotherapy. This specific application of genomic testing highlights a broader trend in oncology: the move away from "one-size-fits-all" treatments toward precision medicine that minimizes patient trauma and optimizes healthcare resources. To date, over two million patients have utilized the Oncotype DX test, underscoring the scale at which Abbott now operates in the oncology space.
Advancing Colorectal Cancer Screening Metrics
Colorectal cancer (CRC) remains one of the most preventable yet deadly forms of cancer, largely due to low screening compliance. Abbott’s current efforts are focused on refining the accuracy of these tests to reduce the burden of false positives and increase the detection of early-stage malignancies. The recent introduction of Cologuard Plus marks a significant milestone in this effort, boasting a 95% detection rate for colorectal cancer and a 94% specificity rate.
In diagnostic terms, sensitivity refers to the test’s ability to correctly identify those with the disease, while specificity measures the ability to correctly identify those without it. High specificity is critical in cancer screening because false positives can lead to unnecessary, invasive procedures like colonoscopies, which carry their own risks and costs. By achieving a 94% specificity, Cologuard Plus positions itself as the premier non-invasive option for patients who may be hesitant to undergo traditional invasive screenings.
The Strategic Collaboration with Freenome
While stool-based tests like Cologuard currently lead the market in non-invasive CRC screening, the industry is racing toward a viable blood-based alternative. Abbott is pursuing a dual-track strategy in this area, developing internal blood-based tests while simultaneously collaborating with Freenome to market their existing blood test.
The data from Freenome has shown promise, particularly in its ability to detect active cancer. However, the primary hurdle for all blood-based CRC tests remains the detection of "precancer"—the adenomas and lesions that can be removed before they turn malignant. Currently, Freenome’s test shows an 18% precancer detection rate. While this is considered "best in class" for blood-based options, it still lags significantly behind stool-based tests and traditional colonoscopies.
Abbott holds exclusive rights in the United States to commercialize and distribute blood-based tests in collaboration with Freenome. This partnership is designed to capture the segment of the population—estimated at roughly 50 million Americans—who are eligible for screening but remain unscreened because they refuse both colonoscopies and stool-based kits. By offering a blood draw as a third option, Abbott aims to drive adherence and compliance, which are directly correlated with lower mortality rates.
The Economics of Blood-Based Testing
A significant barrier to the widespread adoption of blood-based cancer screening is the cost. Most current versions of these tests rely on next-generation sequencing (NGS) technology, which is complex and expensive to perform. In contrast, stool-based tests like Cologuard offer a more favorable health economic profile for insurance providers and public health systems.
Abbott’s internal research and development program is specifically targeting this price disparity. The company is working toward a lower-cost blood-based option that could eventually be scaled for global markets, particularly in regions where the high cost of NGS technology makes it prohibitive. The goal is to democratize early cancer detection by making it as routine and affordable as a standard cholesterol panel.
Multi-Cancer Early Detection: The Next Frontier
Perhaps the most ambitious component of Abbott’s new portfolio is the Cancerguard multi-cancer early detection (MCED) program. Statistical data indicates that approximately 70% of all cancers currently have no recommended routine screening options. This means that seven out of ten cancers are discovered only after the patient becomes symptomatic, often at a stage where the disease is advanced and more difficult to treat.
The rationale behind Cancerguard is an "aggregate approach" to screening. While the prevalence of individual rare cancers may be too low to justify a dedicated screening program for each, the combined prevalence of multiple rare cancers is high enough to make a single, broad-spectrum test cost-effective. Cancerguard is designed to complement, rather than replace, existing modalities like mammography or the Cologuard test.
The test has already been launched commercially in Japan and is currently available in the U.S. as a laboratory-developed test (LDT). Abbott is now preparing for a large-scale prospective study in the United States to support a formal submission for Food and Drug Administration (FDA) review. One of the key differentiators for Cancerguard is its clear path for clinical follow-up; a positive signal triggers a standardized regimen of CT and PET scans to localize the cancer, reducing the "time to resolution" for the patient.
Timeline of Recent Developments and Future Outlook
The integration of Exact Sciences into Abbott’s diagnostic ecosystem is the culmination of several years of strategic maneuvering in the medtech sector:
- March 2024: Abbott completes the $21 billion acquisition of Exact Sciences, marking its largest entry into the oncology market.
- Late 2024: Launch of Cologuard Plus, setting new benchmarks for sensitivity and specificity in non-invasive CRC screening.
- Early 2025: Commercial launch of the Oncodetect MRD test and the Cancerguard MCED test in international markets, including Japan.
- Mid-2025: Continued FDA review of the Freenome blood-based CRC test, with approval anticipated in the near future.
- 2026 and Beyond: Initiation of massive prospective trials in the U.S. to move MCED tests from the LDT category to full FDA clearance.
The broader implications of Abbott’s expansion are significant for the healthcare industry at large. By controlling a portfolio that spans from hereditary risk (Riskguard) to early detection (Cologuard/Cancerguard) and treatment guidance (Oncotype DX), Abbott is positioning itself as an indispensable partner to both oncologists and primary care physicians.
As the 50 million unscreened Americans are slowly brought into the diagnostic fold through more convenient blood and stool options, the potential for a reduction in late-stage cancer diagnoses is high. Furthermore, the ability to monitor for molecular residual disease (MRD) through tests like Oncodetect could redefine how "remission" is managed, allowing for the detection of relapses months before they would appear on traditional imaging.
Abbott’s $21 billion bet on Exact Sciences is more than a financial acquisition; it is a commitment to a future where cancer is managed as a chronic, monitorable condition rather than an unforeseen crisis. With a robust pipeline of blood-based technologies and a dominant position in the stool-based screening market, the company is now the primary architect of the modern cancer care continuum.
